SciCross has been awarded a grant from VINNOVA, with support from Medtech4Heath and Swelife, for the development of a novel way to treat ANCA vasculitis (an autoimmune blood vessel disease). The project will be run in collaboration with Toleranzia AB, Lund University’s Kidney Research Lab and Region Skåne. Additional information can be found in this press release (https://www.toleranzia.com/mfn_news/toleranzia-receives-funding-from-vinnova-for-anca-vasculitis-project/).
Together with scientist from UCL, we have written a review article covering AI technologies in the field of chronic inflammatory disease.
Machine Learning Techniques for Personalised Medicine Approaches in Immune-Mediated Chronic Inflammatory Diseases: Applications and Challenges. Peng J, Jury EC, Dönnes P, Ciurtin C. Front Pharmacol. 2021 Sep 30;12:720694. doi: 10.3389/fphar.2021.720694. eCollection 2021.
Check out the latest Covid-19 related publications. SciCross main contributions in these projects has been the design of Sars-CoV-2 peptides used to study T-cell responses.
An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses, PLoS One. 2021 Sep 30;16(9):e0258041, https://pubmed.ncbi.nlm.nih.gov/34591918/
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19, J Intern Med. 2021 Aug 30, https://pubmed.ncbi.nlm.nih.gov/34459525/
In a collaboration with Novartis, we (SciCross) has developed a method for improved HLA class II binding prediction based on MAPPs data. The results till be presented at the Immunogenicity and Bioassay Summit (https://www.immunogenicitysummit.com/), which in 2020 will be hosted as a virtual conference. And yes, the performance accuracy of the methods is great!